13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      An Nfil3Zeb2Id2 pathway imposes Irf8 enhancer switching during cDC1 development

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Classical type 1 dendritic cells (cDC1s) are required for anti-viral and anti-tumor immunity, which necessitates an understanding of their development. Development of the cDC1 progenitor requires an E protein–dependent enhancer located 41 kilobases downstream of the transcription start site of the transcription factor IRF8 (+41 kb Irf8 enhancer) but its maturation instead requires the BATF3-dependent +32 kb Irf8 enhancer. To understand this switch, we performed single-cell RNA sequencing of the common dendritic cell progenitor (CDP) and identified a cluster of cells that expressed transcription factors that influence cDC1 development, such as Nfil3, Id2, and Zeb2. Genetic epistasis among these factors revealed that Nfil3 expression is required for the transition from Zeb2 hi and Id2 lo CDPs to Zeb2 lo and Id2 hi CDPs, which represent the earliest committed cDC1 progenitors. This genetic circuit blocks E protein activity to exclude plasmacytoid DC potential and explains the switch in Irf8 enhancer usage during cDC1 development.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

          CD4+ T cells have a crucial role in mediating protection against a variety of pathogens through production of specific cytokines. However, substantial heterogeneity in CD4+ T-cell cytokine responses has limited the ability to define an immune correlate of protection after vaccination. Here, using multiparameter flow cytometry to assess the immune responses after immunization, we show that the degree of protection against Leishmania major infection in mice is predicted by the frequency of CD4+ T cells simultaneously producing interferon-gamma, interleukin-2 and tumor necrosis factor. Notably, multifunctional effector cells generated by all vaccines tested are unique in their capacity to produce high amounts of interferon-gamma. These data show that the quality of a CD4+ T-cell cytokine response can be a crucial determinant in whether a vaccine is protective, and may provide a new and useful prospective immune correlate of protection for vaccines based on T-helper type 1 (TH1) cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon.

            We have identified two cell subsets in human blood based on the lack of lineage markers (lin-) and the differential expression of immunoglobulin-like transcript receptor 1 (ILT1) and ILT3. One subset (lin-/ILT3+/ILT1+) is related to myeloid dendritic cells. The other subset (lin-/ILT3+/ILT1+) corresponds to 'plasmacytoid monocytes'. These cells are found in inflamed lymph nodes in and around the high endothelial venules. They express CD62L and CXCR3, and produce extremely large amounts of type I interferon after stimulation with influenza virus or CD40L. These results, with the distinct cell phenotype, indicate that plasmacytoid monocytes represent a specialized cell lineage that enters inflamed lymph nodes at high endothelial venules, where it produces type I interferon. Plasmacytoid monocytes may protect other cells from viral infections and promote survival of antigen-activated T cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development.

              Plasmacytoid dendritic cells (PDCs) represent a unique immune cell type specialized in type I interferon (IFN) secretion in response to viral nucleic acids. The molecular control of PDC lineage specification has been poorly understood. We report that basic helix-loop-helix transcription factor (E protein) E2-2/Tcf4 is preferentially expressed in murine and human PDCs. Constitutive or inducible deletion of murine E2-2 blocked the development of PDCs but not of other lineages and abolished IFN response to unmethylated DNA. Moreover, E2-2 haploinsufficiency in mice and in human Pitt-Hopkins syndrome patients was associated with aberrant expression profile and impaired IFN response of the PDC. E2-2 directly activated multiple PDC-enriched genes, including transcription factors involved in PDC development (SpiB, Irf8) and function (Irf7). These results identify E2-2 as a specific transcriptional regulator of the PDC lineage in mice and humans and reveal a key function of E proteins in the innate immune system.
                Bookmark

                Author and article information

                Journal
                100941354
                21750
                Nat Immunol
                Nat. Immunol.
                Nature immunology
                1529-2908
                1529-2916
                1 July 2019
                12 August 2019
                September 2019
                12 February 2020
                : 20
                : 9
                : 1174-1185
                Affiliations
                [1 ]Department of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, Missouri
                [2 ]Howard Hughes Medical Institute, Washington University in St. Louis, School of Medicine, St. Louis, Missouri
                [3 ]Research Biology, Genentech, South San Francisco, California
                [4 ]Department of Molecular Biology, Genentech, South San Francisco, California
                [5 ]Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA
                [6 ]Deparment of Genetics Stanford University School of Medicine, Stanford, CA, USA
                [7 ]Biophysics Program, Stanford University School of Medicine, Stanford, CA, USA
                [8 ]Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
                [9 ]Department of Oncology, Amgen Inc., South San Francisco, California
                [10 ]Department of Experimental Medicine, University of Perugia, Italy
                [11 ]Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba
                [12 ]Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA
                Author notes
                [13]

                Co-first author;

                AUTHOR CONTRIBUTIONS

                P.B., X.H., T.L., T.L.M., and K.M.M. designed the study; P.B., X.H., and T.L. performed experiments related to analysis of immune populations, cell sorting and culture, gene microarray, and generation of mice with advice from C.G.B., G.E.G.-R., M.G., and S.K.; P.B., M.N., Z.M., and A.S.S performed and analyzed single-cell RNA-sequencing; V.D., J.M.G., A.T.S., and H.Y.C. performed ATAC-seq of DC progenitors; J.M.G. and A.T.S. performed computational analysis of ATAC-seq data; A.I. assisted with analysis of E-box motifs; P.B. performed all retroviral and reporter assays; P.B., X.H., T.L., and K.M.M. wrote the manuscript with advice from all authors.

                [* ]To whom correspondence should be addressed. Phone: 314-362-2009, kmurphy@ 123456wustl.edu
                Article
                NIHMS1532199
                10.1038/s41590-019-0449-3
                6707889
                31406377
                ccc44b39-7b1d-4fd1-9a03-fee1fa80023f

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Immunology
                Immunology

                Comments

                Comment on this article